Mass General: Clinical Trial Finds Targeted Drug Effective in Patients Who Have Lung Cancer With Certain Gene Mutations
September 09, 2020
September 09, 2020
BOSTON, Massachusetts, Sept. 9 (TNSRes) -- Massachusetts General Hospital issued the following news release:
A targeted therapy called capmatinib can provide significant benefits to patients who have advanced lung cancer with specific gene mutations, according to recently published results from a phase two clinical trial.
The trial, which is published in the New England Journal of Medicine, was conducted by an international team led by investigators at Massachusetts Ge . . .
A targeted therapy called capmatinib can provide significant benefits to patients who have advanced lung cancer with specific gene mutations, according to recently published results from a phase two clinical trial.
The trial, which is published in the New England Journal of Medicine, was conducted by an international team led by investigators at Massachusetts Ge . . .